TG Therapeutics (TGTX) Misses Q1 EPS by 6c

TG Therapeutics (NASDAQ: TGTX) reported Q1 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Outlook Therapeutics posts Q3 loss, eyes U.S. LYTENAVA launch by end of 2026
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c